AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy

Monoclonal antibodies against CD20 molecule have been leading the revolution of lymphoma treatment. In addition to monoclonal antibodies against CD20 and CD30, novel agents of immunotherapeutics in clinical development are being developed and are rapidly migrating to clinical application. One area o...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Jingjing, Fu, Jiaping, Zhang, Mingzhi, Liu, Delong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Highlight
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4522136/
https://www.ncbi.nlm.nih.gov/pubmed/26231785
http://dx.doi.org/10.1186/s13045-015-0188-3
_version_ 1782383922477268992
author Wu, Jingjing
Fu, Jiaping
Zhang, Mingzhi
Liu, Delong
author_facet Wu, Jingjing
Fu, Jiaping
Zhang, Mingzhi
Liu, Delong
author_sort Wu, Jingjing
collection PubMed
description Monoclonal antibodies against CD20 molecule have been leading the revolution of lymphoma treatment. In addition to monoclonal antibodies against CD20 and CD30, novel agents of immunotherapeutics in clinical development are being developed and are rapidly migrating to clinical application. One area of active development is NK cell activators, such as AFM13. This review will highlight the latest development of AFM13 as the first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy.
format Online
Article
Text
id pubmed-4522136
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-45221362015-08-02 AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy Wu, Jingjing Fu, Jiaping Zhang, Mingzhi Liu, Delong J Hematol Oncol Research Highlight Monoclonal antibodies against CD20 molecule have been leading the revolution of lymphoma treatment. In addition to monoclonal antibodies against CD20 and CD30, novel agents of immunotherapeutics in clinical development are being developed and are rapidly migrating to clinical application. One area of active development is NK cell activators, such as AFM13. This review will highlight the latest development of AFM13 as the first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy. BioMed Central 2015-08-01 /pmc/articles/PMC4522136/ /pubmed/26231785 http://dx.doi.org/10.1186/s13045-015-0188-3 Text en © Wu et al. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Highlight
Wu, Jingjing
Fu, Jiaping
Zhang, Mingzhi
Liu, Delong
AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy
title AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy
title_full AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy
title_fullStr AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy
title_full_unstemmed AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy
title_short AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy
title_sort afm13: a first-in-class tetravalent bispecific anti-cd30/cd16a antibody for nk cell-mediated immunotherapy
topic Research Highlight
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4522136/
https://www.ncbi.nlm.nih.gov/pubmed/26231785
http://dx.doi.org/10.1186/s13045-015-0188-3
work_keys_str_mv AT wujingjing afm13afirstinclasstetravalentbispecificanticd30cd16aantibodyfornkcellmediatedimmunotherapy
AT fujiaping afm13afirstinclasstetravalentbispecificanticd30cd16aantibodyfornkcellmediatedimmunotherapy
AT zhangmingzhi afm13afirstinclasstetravalentbispecificanticd30cd16aantibodyfornkcellmediatedimmunotherapy
AT liudelong afm13afirstinclasstetravalentbispecificanticd30cd16aantibodyfornkcellmediatedimmunotherapy

Ejemplares similares